CS logo
small CS logo
Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive

Paris, France
Oncologist in Paris
20 Rue Leblanc, 75015 Paris

About Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive


  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender

Clinical Trials at Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive


During the past decade, Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 1 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Clinical Trials Sponsors and Collaborators


In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive" #1 collaborator was "ADIR, a Servier Group company" with 2 trials as a collaborator and "Institut de Recherches Internationales Servier" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

Clinical Trials Conditions at Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive


According to Clinical.Site data, the most researched conditions in "Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive" are "Metastatic Colorectal Cancer" (2 trials), "Colorectal Cancer" (1 trials), "Esophageal Squamous Cell Carcinoma" (1 trials), "Esophageal Squamous Cell Carcinoma (ESCC)" (1 trials) and "Refractory Metastatic Colorectal Cancer" (1 trials). Many other conditions were trialed in "Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive" in a lesser frequency.

Clinical Trials Intervention Types at Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive


Most popular intervention types in "Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive" are "Drug" (6 trials) and "Biological" (1 trials). Other intervention types were less common.
The name of intervention was led by "Bevacizumab" (2 trials), "Capecitabine" (2 trials), "Placebo" (2 trials), "Tislelizumab" (2 trials) and "Bevacizumab control" (1 trials). Other intervention names were less common.

Clinical Trials Genders at Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive


The vast majority of trials in "Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive" are 6 trials for "All" genders.

Clinical Trials Status at Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive


Currently, there are NaN active trials in "Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive, undefined suspended trials, and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".